M.C. Moruzzi

Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women

In post-menopausal period vulvo-vaginal atrophy (VVA)-related symptoms may seriously affect womens quality of life. Hormonal replacement therapy effectively relieves these symptoms but it is not always safe or accepted, and a non-hormonal treatment is often needed instead. Over a period of 12 weeks, we tested the effect of a twice-a-week vulvo-vaginal application of a hyaluronic acid, AC collagen, isoflavones and vitamins-based cream (Perilei Pausa®) on 35 women in post-menopausal period, reporting VVA-related symptoms. After 12 weeks of treatment with Perilei Pausa® a significant improvement in vaginal dryness, vulvo-vaginal itching, dyspareunia (P < 0.001), dysuria (P = 0.02), nocturia (P = 0.009) and pollakiuria (P = 0.005) was reported by the women. Colposcopical score assessing the intensity of atrophic colpitis, cervico-vaginal paleness and petechiae was also reduced (P = 0.037, P = 0.016 and P = 0.032, respectively). No significant difference in terms of maturation value of cervico-vaginal epithelium was observed. In conclusion, Perilei Pausa® may represent an effective and safe alternative treatment of symptomatic VVA in post-menopausal women.

Ovarian masses with papillary projections diagnosed and removed during pregnancy: ultrasound features and histological diagnosis

To elucidate the ultrasound features that can discriminate between benign and malignant ovarian cysts with papillary projections but no other solid component in pregnant women.

Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non‐invasive malignant serous ovarian tumors

To describe clinical and ultrasound features of different subclasses of malignant serous ovarian tumors according to the World Health Organization 2014 classification.

PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to predict partial response in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery

Chemoradiation‐based neoadjuvant treatment followed by radical surgery is an alternative therapeutic strategy for locally advanced cervical cancer (LACC), but ultrasound variables used to predict partial response to neoadjuvant treatment are not well defined. Our goal was to analyze prospectively the potential role of transvaginal ultrasound in early prediction of partial pathological response, assessed in terms of residual disease at histology, in a large, single‐institution series of LACC patients triaged to neoadjuvant treatment followed by radical surgery.

Imaging in gynecological disease (13): clinical and ultrasound characteristics of endometrioid ovarian cancer

To describe the clinical and ultrasound characteristics of ovarian pure endometrioid carcinomas.

OP03.08: Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses: Short oral presentation abstracts

F. Moro1, T. Pasciuto1, D. Djokovic1, A. Di Legge1, V. Granato1, M. Moruzzi2, R. Mancari3, F. Mascilini2, G. Zannoni4, D. Fischerová5, D. Franchi3, G. Scambia1, A.C. Testa1 1Department of Woman and Child Health, Università Cattolica del Sacro Cuore, Rome, Italy; 2Department of Woman and Child Health, Fondazione A Gemelli, Rome, Italy; 3Preventive Gynecology Unit, Division of Gynecology, European Institute of Oncology, Milan, Italy; 4Institute of Histopathology, Università Cattolica del Sacro Cuore, Rome, Italy; 5Charles University, Prague, Czech Republic

PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to predict partial response in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery: Cervical cancer and ultrasound

Chemoradiation‐based neoadjuvant treatment followed by radical surgery is an alternative therapeutic strategy for locally advanced cervical cancer (LACC), but ultrasound variables used to predict partial response to neoadjuvant treatment are not well defined. Our goal was to analyze prospectively the potential role of transvaginal ultrasound in early prediction of partial pathological response, assessed in terms of residual disease at histology, in a large, single‐institution series of LACC patients triaged to neoadjuvant treatment followed by radical surgery.

P30.03: Imaging in gynecological disease: clinical and ultrasound features of ovarian endometrioid carcinoma

Methods: From a group of consecutive patients suspected for ovarian cancer (OC) (symptoms, ascites, elevated cancer antigen (CA) 125) and who underwent laparotomy, 14 had PPC (tumour disseminated on the peritoneum without or with only minimal ovaries involvement). Before surgery all patient underwent standardised transvaginal and abdominal ultrasound examination with predefined definitions (images and videos stored) so to calculate RMI, LR2, ADNEX, SR. A subjective assessment was to discriminate between malignant and benign disease in a 6 point score. Results: High RMI was assessed in all cases. Tumours were classified as malignant (n=3) or inconclusive (n=11) with IOTA-SR. Median value of LR2 was 75.1% (range: 34.7-94.9). Median values of ADNEX model calculations were as follows: risk of malignancy-98.6% (range: 85.6-99.9), risk of stage II-IV OC-89.9%, risk of stage I OC -1.1%, risk of borderline tumour-0.45%, risk of metastatic cancer-7.4%. Once ADNEX model was calculated without CA125, in all cases with ascites the risk of malignancy was still over 91%, while in patients without ascites (n=3) this value was 58-63%. In subjective assessment all patients were suspected for malignancy. There were no pelvic tumours with locules, nor with papillations. Ascites and metastatic tumours in abdominal cavity were detected in 11 and 12 patients respectively. Median ultrasound diameter of ovaries or ovarian involvement was 34mm. Median concentration of CA125 was 928 U/ml (98-7000). Conclusions: In cases with PPC, the RMI, ADNEX model and subjective ultrasound assessment can predict malignancy with a very high accuracy. Evaluation of CA125 should be considered, both as a single diagnostic measure and a part of ADNEX model. IOTA-SR has limited value in diagnosing PPC.

Prospective multimodal imaging assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery. The PRICE (PRospective Imaging of CErvical cancer and neoadjuvant treatment) study: the role of ultrasound

Chemoradiation‐based neoadjuvant treatment followed by radical surgery is an alternative therapeutic strategy for locally advanced cervical cancer (LACC), but ultrasound variables used to predict partial response to neoadjuvant treatment are not well defined. Our goal was to analyze prospectively the potential role of transvaginal ultrasound in early prediction of partial pathological response, assessed in terms of residual disease at histology, in a large, single‐institution series of LACC patients triaged to neoadjuvant treatment followed by radical surgery.

W110 THE SONOGRAPHIC PREDICTION OF INVASIVE CARCINOMA IN UNILOCULAR-SOLID OVARIAN CYSTS IN PREMENOPAUSAL PATIENTS: A PILOT STUDY

of uterine malformations. Hysteroscopy appeared to have strongsensitivity (90.4%) and specificity (100%) and PPV (100%) in uterine myomas detection, and exceptional sensitivity (100%) and specificity (90.4%) in the diagnosis of uterine malformations. Both showed high accuracy (93.7%) in myomas detection, 3D-TVS had a slightly higher accuracy in the diagnosis of uterine malformations (96.8% vs 93.7%). Conclusions: 3D-TVS shows a good value in a primary assessment of uterine myomas and malformations for excluding uterine pathologies and confirming their presence, and could be used to avoid unnecessary diagnostic Hysteroscopies in healthy women, and could be helpful, after diagnostic hysteroscopy, to assess the pathologies of uterine wall, in the differential diagnosis of uterine septum and bicornuate uteri.